echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Lancet Sub-Journal: Safety and Effectiveness of Intensive Antihypertensive Therapy in Endovascular Therapy for Acute Stroke

    Lancet Sub-Journal: Safety and Effectiveness of Intensive Antihypertensive Therapy in Endovascular Therapy for Acute Stroke

    • Last Update: 2021-03-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Stroke is the third leading cause of death and disability in the world, thus causing a huge economic and social burden.


    About 84.


    Mechanical treatment of intravascular thrombus benefit resection (MT), the success rate of recanalization can be increased to 70-80% endovascular mechanical thrombus benefit resection (MT), the success rate of recanalization can be increased to 70-80% thrombus

    In order to ensure that LVO patients can get the most benefit from MT, various clinical attempts have been made, including pre-hospital screening and scheduling systems to minimize transportation time, emergency stroke severity scale and neuroimaging Scientific evaluation, timely selection of qualified patients, and improvement of reperfusion therapy and catheters to improve the complete reperfusion rate.


    Screening

    High systolic blood pressure after successful endovascular treatment of acute ischemic stroke is associated with an increased risk of intracranial hemorrhage.


    High systolic blood pressure after successful endovascular treatment of acute ischemic stroke is associated with an increased risk of intracranial hemorrhage.


    Researchers conducted a multi-center, open-label, randomized controlled trial in four academic hospital centers in France.


    In both groups, the target systolic blood pressure must be reached within 1 hour after randomization and maintained by intravenous antihypertensive therapy for 24 hours.


    A total of 162 patients were randomly assigned to the intensive target group and the standard target group.


    65 (42%) of the 154 patients in the intensive target group and 68 (43%) of the 157 patients in the standard target group had intracranial hemorrhage observed in brain CT within 24-36 h after reperfusion, no significant statistics Learn the difference.


    At the same time, there was no significant difference in hypotension events between the two groups.


    In general, compared with the standard care systolic blood pressure target of 130-185 mmHg, the enhanced systolic blood pressure target of 100-129 mmHg after successful endovascular treatment does not reduce the rate of intracranial hemorrhage 24-36 h.


    Compared with the standard care systolic blood pressure target of 130-185 mmHg, the enhanced systolic blood pressure target of 100-129 mmHg after successful endovascular treatment does not reduce the rate of intracranial hemorrhage 24-36 h.


    references:

    Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial.


    Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.